About the Company

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company with a journey spanning over four decades. Incorporated in 1981, the Company set up its first manufacturing facility in 1983, entered Indian domestic branded generics in 1995, and has steadily expanded across formulations, APIs, injectables and biologics, as well as front-end operations in key global markets. 

Emcure develops and manufactures complex generics, biosimilars and novel drug delivery systems, with strategic focus areas including complex injectables (such as liposomal and long-acting formats), biologics, peptides, ADCs and vaccines. The Company operates 13 state-of-the-art manufacturing facilities in India, supplying to domestic and international markets, with approvals from global regulators including USFDA, EU-GMP, TGA, UK‑MHRA, Health Canada and WHO‑GMP . Emcure has a diversified presence across 70+ countries, with international operations constituting a majority of Group revenues .

Key milestones include the launch of India’s first thermostable mRNA COVID‑19 vaccine (Emergency Use Authorisation as the first Indian company and third globally), first‑in‑India chiral molecules, and the first and only generic approval for Liposomal Amphotericin B in the European Union. The Company was listed on the Indian stock exchanges (NSE and BSE) on July 10, 2024. . As at March 31, 2025, the Group comprised 23 subsidiaries (direct and indirect) across India, North America, Europe, LATAM, Africa and Asia .

Business Segments

– Domestic vs. International: Domestic contributed 46.3% and International 53.7% of revenue in FY2024‑25  .

Key Management

– Satish Mehta – Managing Director & CEO

– Sunil Mehta – Whole‑time Director

– Dr. Mukund Gurjar – Whole‑time Director

– Mrs. Namita Thapar – Whole‑time Director

– Mr. Samit Mehta – Whole‑time Director

– Mr. Tajuddin Shaikh – Chief Financial Officer

– Mr. Chetan Sharma – Company Secretary & Compliance Officer

Latest Updates

– Product and regulatory milestones: Received approval for Liposomal Amphotericin B in the UK and EU, becoming the first and only generic in the EU for this complex product .

– Strategic partnerships and portfolio actions: In‑licensed Lenacapavir from Gilead to strengthen leadership in ARVs; entered a distribution agreement with Sanofi to market its cardiovascular portfolio in India; acquired the product portfolio of Manx Healthcare in the UK, adding 100+ dossiers to the pipeline  .

– Market expansion: Successfully integrated Mantra Pharma in Canada, enabling a pan‑Canada front‑end presence and deepening access to Quebec .

– New launches and businesses: Launched Emcutix, a dedicated dermatology subsidiary; forayed into consumer health under the Arth brand and announced actor Vidya Balan as brand ambassador  .

– R&D and innovation: Commissioned a new Emcure Research Centre in Gujarat; secured a $13.38 Million CEPI grant for an mRNA‑based Nipah vaccine; reinforced pipeline in GLP‑1s, biosimilars (r‑Asparaginase, Bevacizumab) and novel drug delivery systems .

– Operations footprint: The Company reported international operations as a majority of Group revenue, reflecting continued scale‑up across Canada/North America, Europe and Rest of World markets .